Nuvalent (NUVL)
(Delayed Data from NSDQ)
$74.11 USD
+1.95 (2.70%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $74.12 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NUVL 74.11 +1.95(2.70%)
Will NUVL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NUVL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVL
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
NUVL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Sep 17, 2024
Other News for NUVL
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight
Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
Nuvalent Inc Reports Q2 2025 EPS of -$1.39, Missing Estimates; Net Loss Reaches $99.7 Million
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, ...
Paradigm Biocapital Advisors LP Acquires 1,128,613 Shares in Cidara Therapeutics Inc